Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q1)Jun 30, 2025 | (FY)Mar 31, 2025 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 83.43%1.17B | 101.24%4.74B | -22.06%635.53M | 138.27%2.36B | 220.99%530.99M | 496.02M | 514.6M | 815.45M | 46.74%989.24M | 165.42M |
| Cost of revenue | 76.80%933.79M | 74.88%2.5B | 116.82%528.15M | 227.36%1.43B | 1,035.49%407.41M | 377.41M | 400.4M | 243.59M | 28.54%436.47M | 35.88M |
| Gross profit | 116.03%231.96M | 141.80%2.24B | -81.22%107.37M | 67.92%928.24M | -4.61%123.58M | 118.61M | 114.2M | 571.85M | 65.21%552.77M | 129.54M |
| Operating expense | 3.03%2.48B | 87.24%12.04B | 42.86%2.4B | -44.46%6.43B | 4.19%1.88B | 1.83B | 1.05B | 1.68B | 163.63%11.58B | 1.8B |
| Staff costs | ---- | 52.65%1.52B | ---- | 42.37%997.2M | ---- | ---- | ---- | ---- | 70.19%700.45M | ---- |
| Selling and administrative expenses | ---- | 74.34%2.79B | ---- | -2.69%1.6B | ---- | ---- | ---- | ---- | 125.68%1.64B | ---- |
| -General and administrative expense | ---- | 74.34%2.79B | ---- | -2.69%1.6B | ---- | ---- | ---- | ---- | 125.68%1.64B | ---- |
| Research and development costs | ---- | 101.62%7.73B | ---- | -58.47%3.83B | ---- | ---- | ---- | ---- | 183.95%9.23B | ---- |
| Operating profit | 2.26%-2.24B | -78.04%-9.8B | -106.80%-2.3B | 50.09%-5.5B | -4.87%-1.75B | -1.71B | -931.18M | -1.11B | -171.75%-11.02B | -1.67B |
| Net non-operating interest income (expenses) | -96.28%-326.63M | -79.00%-1.2B | -107.78%-166.41M | -242.12%-670.17M | -517.57%-423.09M | -103.79M | -63.19M | -80.09M | -340.89%-195.89M | -68.51M |
| Non-operating interest income | 99.17%30.37M | 414.39%95.75M | --15.25M | 6,820.07%18.62M | 5,644.00%12.92M | --3.2M | ---- | ---- | --269K | --225K |
| Non-operating interest expense | 96.52%357M | 150.12%920.44M | 216.73%181.66M | 87.61%368M | 100.72%137.97M | --106.99M | --65.69M | --57.36M | 686.26%196.16M | --68.74M |
| Total other finance cost | ---- | 16.87%374.89M | ---- | --320.79M | --298.05M | --0 | --0 | --22.74M | ---- | ---- |
| Net investment income | -135.44%-304.41M | -200.50%-644.23M | 198.04%858.93M | 667.85%641.01M | 989.60%737.12M | -499.47M | 115.16M | 288.2M | 25.09%83.48M | 67.65M |
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
| Income from associates and other participating interests | ||||||||||
| Special income (charges) | 0 | -116.59%-622.22M | -923K | 1,080,906.05%3.75B | 111.53%40K | -43.3M | 93.09%-347K | -347K | ||
| Less:Other special charges | ---- | 100.03%1.13M | --923K | -1,080,906.05%-3.75B | ---40K | --43.3M | ---- | ---- | -93.09%347K | ---- |
| Less:Write off | ---- | --621.08M | ---- | --0 | ---- | ---- | ---- | ---- | ---- | ---- |
| Other non-operating income (expenses) | -115.30%-4.09M | 153.68%304.46M | 105.64%26.7M | -134.36%-567.13M | -684.87%-68.77M | -21.81M | -2.85M | -473.7M | -4,946.80%-241.99M | 11.76M |
| Income before tax | -82.54%-2.88B | -409.32%-11.96B | -14.65%-1.58B | 79.37%-2.35B | 9.23%-1.51B | -2.38B | 2.91B | -1.38B | -181.36%-11.38B | -1.66B |
| Income tax | -56.18%950K | -161.98%-11.57M | 430.49%2.17M | -4.73%18.67M | 10.47%21.7M | -1.23M | -1.14M | -656K | 24.70%19.6M | 19.64M |
| Net income | -82.35%-2.88B | -404.81%-11.95B | -14.86%-1.58B | 79.24%-2.37B | 9.00%-1.53B | -2.37B | 2.91B | -1.37B | -180.75%-11.4B | -1.68B |
| Net income continuous operations | -82.35%-2.88B | -404.81%-11.95B | -14.86%-1.58B | 79.24%-2.37B | 9.00%-1.53B | ---2.37B | --2.91B | ---1.37B | -180.75%-11.4B | ---1.68B |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | -82.35%-2.88B | -404.81%-11.95B | -14.86%-1.58B | 79.24%-2.37B | 9.00%-1.53B | -2.37B | 2.91B | -1.37B | -180.75%-11.4B | -1.68B |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | -82.35%-2.88B | -404.81%-11.95B | -14.86%-1.58B | 79.24%-2.37B | 9.00%-1.53B | -2.37B | 2.91B | -1.37B | -180.75%-11.4B | -1.68B |
| Gross dividend payment | ||||||||||
| Basic earnings per share | -60.59%-27.22 | -327.95%-124.32 | 3.42%-16.95 | 86.26%-29.05 | 40.03%-18.7 | -29.54 | 36.74 | -17.55 | -172.21%-211.4691 | -31.1799 |
| Diluted earnings per share | -60.59%-27.22 | -327.95%-124.32 | 3.42%-16.95 | 86.26%-29.05 | 40.03%-18.7 | -29.54 | 35.419 | -17.55 | -172.21%-211.4691 | -31.1799 |
| Dividend per share | ||||||||||
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |